Our company present an innovative technology for using electrets to fight with one of the toughest diseases, namely osteoarthritis. Our development has no analogues in the world neither at the medical device level nor at the treatment method level. The method of treatment is promoted under the IMPLESO trademark. The essence of the new treatment method is a minimally invasive surgery to insert an electret implant into the joint bone. The electret implant is a rod of tantalum coated with a thin layer of anodic oxide in the electret state. The necessary charge distribution is created on its surface. In this state, the implant forms around itself a constant electric field without external power supplies. Minimally invasive and low traumatic surgery lasts from 15 to 40 minutes under local anesthesia and practically has no contraindications. The method application has shown not only the possibility of stopping the disease progress, but also the bright results of facilitating its manifestations. The patient already feels the first signs of improvement in 2-3 days after the surgery. Then the intensity of pain is reduced and range of motions is improved. Then within 6 months the effect of treatment increases reaching a maximum in the range of 6-12 months. IMPLESO does not directly compete with any of currently used methods for osteoarthritis treatment. This method is most effective in 1st-2nd and early 3rd stages.
LLC Medel was founded in 2013 to create a mass production and sale of electret implants for the osteoarthritis treatment. Russian Startup Rating gave rating A to the project in 2013, and the project got to the top 50 Russian startups. In 2014 the project became the Skolkovo Innovation Center resident. In 2014 the project became the winner of Finlanding (http://www.finlanding.fi) - the first Finnish-Russian program to support output of high-tech companies on the European markets. In 2014 the company attracted a private investment on R&D and registration of medical device in Russia. In May 2017, successfully completing clinical trials, our medical device received Roszdravnadzor registration certificate. In the autumn of 2017, Medel completed the licensing of production. Now IMPLESO surgeries are already performed in 10 cities of Russia and continue to gain popularity.